New perspectives on antimicrobial agents: Ceftolozane-tazobactam

Bryan D. Lizza, Kevin D. Betthauser, David J. Ritchie, Scott T. Micek, Marin H. Kollef

Research output: Contribution to journalReview articlepeer-review

18 Scopus citations


Ceftolozane-tazobactam (C/T) is a new fifth-generation cephalosporin/ beta-lactamase inhibitor combination approved by the Food and Drug Administration and the European Medicines Agency for treatment of complicated intraabdominal infections, complicated urinary tract infections, and hospital-acquired pneumonia in adult patients. This review will briefly describe the pharmacology of C/T and focus on the emerging clinical trial and real-world data supporting its current utilization. Additionally, our synthesis of these data over time has set our current usage of C/T at Barnes-Jewish Hospital (BJH). C/T is primarily employed as directed monotherapy at BJH when Pseudomonas aeruginosa isolates are identified with resistance to other beta-lactams. C/T can also be used empirically in specific clinical situations at BJH prior to microbiological detection of an antibiotic-resistant P. aeruginosa isolate. These situations include critically ill patients in the intensive care unit (ICU) setting, where there is a high likelihood of infection with multidrug-resistant (MDR) P. aeruginosa; patients failing therapy with a carbapenem; specific patient populations known to be at high risk for infection with MDR P. aeruginosa (e.g., lung transplant and cystic fibrosis patients); and patients know to have previous infection or colonization with MDR P. aeruginosa.

Original languageEnglish
Article numbere02318-20
JournalAntimicrobial agents and chemotherapy
Issue number7
StatePublished - Jul 2021


  • Antimicrobial resistance


Dive into the research topics of 'New perspectives on antimicrobial agents: Ceftolozane-tazobactam'. Together they form a unique fingerprint.

Cite this